Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice

Current HIV Research
Miguel GenebatManuel Leal

Abstract

to analyze the long-term immunovirological effect and tolerability of a maraviroc-containing antiretroviral therapy in viraemic and pretreated HIV-infected patients with a high prevalence of hepatitis C virus (HCV) coinfection. forty-six R5 HIV-infected patients (48% HCV-coinfected) started a maraviroc-containing antiretroviral regimen, including patients with multidrug resistant virus and patients after first virologic failure. A retrospective study was performed, analysing percentage of patients with undetectable viral load, mean CD4+ gain, liver enzymes, clinical events and treatment modification up to week 48. Raltegravir plus a boosted protease inhibitor was combined with maraviroc in 65.2% of the patients (mainly patients with multidrug resistant virus), while the coformulation lamivudine/abacavir was combined with maraviroc in 26.1% (all of them patients after first virologic failure). After 48 weeks on maraviroc-containing regimen, 96.3% of the patients had achieved undetectability and a mean CD4+ count increase of 151 cells/mm3 was observed. Liver enzymes did not increase along the follow up. One patient died after 24 weeks follow up due to heroin overdose. One patient developed a non-Hodgkin lymphoma after 36 weeks fo...Continue Reading

Citations

May 2, 2012·Antimicrobial Agents and Chemotherapy·Alejandro Gonzalez-SernaEzequiel Ruiz-Mateos
Nov 2, 2012·Expert Review of Anti-infective Therapy·Steven F L van LelyveldAndy I M Hoepelman
Jul 27, 2011·Expert Opinion on Pharmacotherapy·Giuliano Rizzardini, Patrizia Zucchi
Nov 21, 2015·International Journal of Antimicrobial Agents·S F L van LelyveldA I M Hoepelman
Aug 3, 2016·Antimicrobial Agents and Chemotherapy·A Gonzalez-SernaE Ruiz-Mateos
May 18, 2019·International Journal of Molecular Sciences·Donatella AldinucciNaike Casagrande

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.